Human red blood cell concentrates drawn from normal healthy volunteers with hematocrits of 85 volume% were stored in CPDA-1, CPDA-2, or CPDA-3 (citrate-phosphate-dextrose-adenine) anticoagulant at 4° for 35 days.After liquid storage the red blood cell concentrates were biochem. treated with a solution containing 100 mM pyruvate, 100 mM inosine, 100 mM phosphate, and 5 mM adenine to increase their 2,3-DPG and ATP levels which had deteriorated during storage at 4°.The rejuvenated red blood cells were frozen with 40% (weight/volume) glycerol in the poly(vinyl chloride) plastic primary collection bag and were stored at -80° for ≤3 mo.After thawing, the red blood cells were washed and stored at 4° for 24 h prior to autologous transfusion.The CPDA-1-stored red blood cells had a 24-h posttransfusion survival of 82%, and the index of therapeutic effectiveness (ITE) was 75%.The CPDA-2-stored red blood cells had a survival of 85%, with an ITE of 79%.The survival of the CPDA-3-stored red blood cells was 90%, and the ITE was 84%.All units had improved O delivery capacity, with 2,3-DPG and ATP levels of ∼150% of normal after thawing and storage at 4° for 24 h.